1. Home
  2. AMWL vs IFRX Comparison

AMWL vs IFRX Comparison

Compare AMWL & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Well Corporation

AMWL

American Well Corporation

HOLD

Current Price

$5.40

Market Cap

72.7M

Sector

Technology

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$0.86

Market Cap

60.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMWL
IFRX
Founded
2006
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.7M
60.6M
IPO Year
2020
2017

Fundamental Metrics

Financial Performance
Metric
AMWL
IFRX
Price
$5.40
$0.86
Analyst Decision
Hold
Strong Buy
Analyst Count
7
6
Target Price
$7.58
$8.50
AVG Volume (30 Days)
97.4K
539.5K
Earning Date
02-12-2026
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$265,023,000.00
$73,729.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,054.36
P/E Ratio
N/A
N/A
Revenue Growth
4.33
N/A
52 Week Low
$3.71
$0.71
52 Week High
$12.95
$2.77

Technical Indicators

Market Signals
Indicator
AMWL
IFRX
Relative Strength Index (RSI) 55.45 39.99
Support Level $4.18 $0.81
Resistance Level $5.08 $0.90
Average True Range (ATR) 0.29 0.07
MACD 0.00 -0.00
Stochastic Oscillator 68.38 20.14

Price Performance

Historical Comparison
AMWL
IFRX

About AMWL American Well Corporation

American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: